HLB Panagene Strengthens Global Presence in In-Vitro Diagnostics at Medlab Middle East 2025

· HLB Panagene and Biosquare showcase cutting-edge diagnostics at major Middle East exhibition.

 

HLB Panagene and Biosquare participate in Medlab Middle East 2025. (Credit: HLB Panagene)

HLB Panagene, in conjunction with its subsidiary Biosquare, is participating in Medlab Middle East 2025 (Medlab 2025), held at the Dubai World Trade Centre from February 3-6. The company's dedicated booth at the event underscores its strategic initiative to expand its reach within the global in-vitro diagnostics (IVD) market.

Medlab 2025, the largest international exhibition specializing in diagnostics and medical devices with a focus on the Middle East, anticipates over 20,000 attendees and more than 800 exhibitors representing 180 countries. On the exhibition's opening day, HLB Panagene’s booth hosted over 1,000 visitors and engaged in business discussions with more than 40 companies from seven countries across Europe, Asia, and the Middle East.

HLB Panagene and Biosquare are leveraging this platform to showcase their advanced diagnostic technologies to a global audience. HLB Panagene is highlighting its Peptide Nucleic Acid (PNA)-based molecular diagnostics, while Biosquare is promoting its Quantum Dot-based immunodiagnostic solutions, which recently received U.S. Food and Drug Administration (FDA) registration.

A primary objective for HLB Panagene at Medlab 2025 is to strengthen existing partnerships within the Middle East and cultivate new export opportunities in additional markets. The Middle East has been identified as a high-growth market due to its substantial reliance on imported medical devices and increasing governmental investment in healthcare. Leveraging its established regional distribution network, HLB Panagene anticipates significant positive outcomes from its participation in the event.

"Medlab 2025 represents the inaugural global presentation of Biosquare’s diagnostic technology since its FDA registration, and we have already experienced considerable interest from the first day," stated Jang In-geun, CEO of HLB Panagene. "We intend to capitalize on this opportunity to accelerate our expansion into international markets."

Through its presence at Medlab 2025, HLB Panagene aims to solidify its global standing within the IVD sector while continuing to drive innovation in diagnostic technology.

Read more: https://www.ittimes.com/news/articleView.html?idxno=63688

HLB Panagene Strengthens Global Presence in In-Vitro Diagnostics at Medlab Middle East 2025 - IT타임스